Related references
Note: Only part of the references are listed.Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma
Su Jin Lee et al.
INVESTIGATIONAL NEW DRUGS (2012)
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
Ario Takeuchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
Seiji Naito et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma
Junji Furuse et al.
CANCER SCIENCE (2010)
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer
Masahiro Komoto et al.
CANCER SCIENCE (2010)
Multicenter Phase II Trial of S-1 in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Seiji Naito et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification
Junko Tanizaki et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non-small cell Lung Cancer Cell Lines with MET Amplification
Takafumi Okabe et al.
CLINICAL CANCER RESEARCH (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study
Junji Furuse et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
Takafumi Okabe et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A late phase II study of S-1 for metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Thymidylate synthase: A critical target in cancer therapy?
YM Rustum
FRONTIERS IN BIOSCIENCE-LANDMARK (2004)
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma
K Shirao et al.
CANCER (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
M Kawahara et al.
BRITISH JOURNAL OF CANCER (2001)
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
G Milano et al.
EUROPEAN JOURNAL OF CANCER (2000)
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer
W Koizumi et al.
ONCOLOGY (2000)
Share Paper
